White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis

References

1. 1.↵
   2. Compston A,
   3. Coles A

   . Multiple sclerosis. Lancet 2008;372:1502–17 doi:10.1016/S0140-6736(08)61620-7 pmid:18970977

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Geurts JJ,
   3. Calabrese M,
   4. Fisher E, et al

   . Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11:1082–92 doi:10.1016/S1474-4422(12)70230-2 pmid:23153407

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Schulz D,
   3. Kopp B,
   4. Kunkel A, et al

   . Cognition in the early stage of multiple sclerosis. J Neurol 2006;253:1002–10 doi:10.1007/s00415-006-0145-8 pmid:16609812

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Chiaravalloti ND,
   3. DeLuca J

   . Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139–51 doi:10.1016/S1474-4422(08)70259-X pmid:19007738

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Hulst HE,
   3. Steenwijk MD,
   4. Versteeg A, et al

   . Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology 2013;80:1025–32 doi:10.1212/WNL.0b013e31828726cc pmid:23468546

   Abstract/FREE Full Text
6. 6.↵
   2. Roosendaal SD,
   3. Geurts JJ,
   4. Vrenken H, et al

   . Regional DTI differences in multiple sclerosis patients. Neuroimage 2009;44:1397–403 doi:10.1016/j.neuroimage.2008.10.026 pmid:19027076

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Schoonheim MM,
   3. Vigeveno RM,
   4. Rueda Lopes FC, et al

   . Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline. Hum Brain Mapp 2014;35:2348–58 doi:10.1002/hbm.22332 pmid:23982918

   CrossRefPubMed
8. 8.↵
   2. Dineen RA,
   3. Vilisaar J,
   4. Hlinka J, et al

   . Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009;132:239–49 pmid:18953055

   Abstract/FREE Full Text
9. 9.↵
   2. Miller DH,
   3. Soon D,
   4. Fernando KT, et al

   ; RM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390–401 doi:10.1212/01.wnl.0000260064.77700.fd pmid:17452584

   Abstract/FREE Full Text
10. 10.↵
    2. Polman CH,
    3. O'Connor PW,
    4. Havrdova E, et al

    ; RM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910 doi:10.1056/NEJMoa044397 pmid:16510744

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Kurtzke JF

    . Rating neurologic impairment in multiple-sclerosis: an expanded disability status scale (EdSS). Neurology 1983;33:1444–52 doi:10.1212/WNL.33.11.1444 pmid:6685237

    Abstract/FREE Full Text
12. 12.↵
    2. Polman CH,
    3. Reingold SC,
    4. Edan G, et al

    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–46 pmid:16283615

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Steenwijk MD,
    3. Pouwels PJ,
    4. Daams M, et al

    . Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). Neuroimage Clin 2013;3:462–69 doi:10.1016/j.nicl.2013.10.003 pmid:24273728

    CrossRefPubMed
14. 14.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 pmid:12482100

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Chard DT,
    3. Jackson JS,
    4. Miller DH, et al

    . Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010;32:223–28 doi:10.1002/jmri.22214 pmid:20575080

    CrossRefPubMed
16. 16.↵
    2. Smith SM,
    3. Jenkinson M,
    4. Johansen-Berg H, et al

    . Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487–505 pmid:16624579

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Rao SM,
    3. Leo GJ,
    4. Bernardin L, et al

    . Cognitive dysfunction in multiple-sclerosis, 1: frequency, patterns, and prediction. Neurology 1991;41:685–91 pmid:2027484

    Abstract/FREE Full Text
18. 18.↵
    2. Walker LAS,
    3. Mendella PD,
    4. Stewart A, et al

    . Meaningful change in cognition in multiple sclerosis: method matters. Can J Neurol Sci 2011;38:282–88 pmid:21320834

    CrossRefPubMed
19. 19.↵
    2. Vercoulen JH,
    3. Swanink CM,
    4. Fennis JF, et al

    . Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383–92 pmid:7965927

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Zigmond AS,
    3. Snaith RP

    . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70 pmid:6880820

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Bammer R,
    3. Augustin M,
    4. Strasser-Fuchs S, et al

    . Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med 2000;44:583–91 pmid:11025514

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Budde MD,
    3. Xie M,
    4. Cross AH, et al

    . Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis. J Neurosci 2009;29:2805–13 doi:10.1523/JNEUROSCI.4605-08.2009 pmid:19261876

    Abstract/FREE Full Text
23. 23.↵
    2. Budde MD,
    3. Kim JH,
    4. Liang HF, et al

    . Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med 2007;57:688–95 pmid:17390365

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Song SK,
    3. Sun SW,
    4. Ramsbottom MJ, et al

    . Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002;17:1429–36 pmid:12414282

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Song SK,
    3. Yoshino J,
    4. Le TQ, et al

    . Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005;26:132–40 pmid:15862213

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Schmierer K,
    3. Wheeler-Kingshott CA,
    4. Boulby PA, et al

    . Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage 2007;35:467–77 pmid:17258908

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Yednock TA,
    3. Cannon C,
    4. Fritz LC, et al

    . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63–66 pmid:1538783

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Fox RJ,
    3. Cronin T,
    4. Lin J, et al

    . Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol 2011;32:85–91 doi:10.3174/ajnr.A2238 pmid:20947644

    Abstract/FREE Full Text
29. 29.↵
    2. Magraner M,
    3. Coret F,
    4. Casanova B

    . The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. Eur J Radiol 2012;81:3485–90 doi:10.1016/j.ejrad.2012.01.028 pmid:22391507

    CrossRefPubMed
30. 30.↵
    2. Sastre-Garriga J,
    3. Tur C,
    4. Pareto D, et al

    . Brain atrophy in natalizumab-treated patients: a 3-year follow-up. Mult Scler 2015;21:749–56 doi:10.1177/1352458514556300 pmid:25392330

    Abstract/FREE Full Text
31. 31.↵
    2. Iaffaldano P,
    3. Viterbo RG,
    4. Paolicelli D, et al

    . Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 2012;7:e35843 doi:10.1371/journal.pone.0035843 pmid:22558238

    CrossRefPubMed
32. 32.↵
    2. Lang C,
    3. Reiss C,
    4. Mäurer M

    . Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol 2012;67:162–66 doi:10.1159/000334722 pmid:22269396

    CrossRefPubMed
33. 33.↵
    2. Mattioli F,
    3. Stampatori C,
    4. Bellomi F, et al

    . Natalizumab efficacy on cognitive impairment in MS. Neurol Sci 2011;31(suppl 3):321–23 doi:10.1007/s10072-010-0351-0 pmid:20535512

    CrossRefPubMed
34. 34.↵
    2. Mattioli F,
    3. Stampatori C,
    4. Capra R

    . The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011;32:83–88 doi:10.1007/s10072-010-0412-4 pmid:20872033

    CrossRefPubMed
35. 35.↵
    2. Portaccio E,
    3. Stromillo ML,
    4. Goretti B, et al

    . Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Eur J Neurol 2013;20:986–90 doi:10.1111/j.1468-1331.2012.03882.x pmid:23057658

    CrossRefPubMed
36. 36.↵
    2. Stephenson JJ,
    3. Kern DM,
    4. Agarwal SS, et al

    . Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Health Qual Life Outcomes 2012;10:155 doi:10.1186/1477-7525-10-155 pmid:23270428

    CrossRefPubMed
37. 37.↵
    2. Svenningsson A,
    3. Falk E,
    4. Celius EG, et al

    ; Tynergy Trial Investigators. Natalizumab treatment reduces fatigue in multiple sclerosis: results from the TYNERGY trial—a study in the real life setting. PLoS One 2013;8:e58643 doi:10.1371/journal.pone.0058643 pmid:23555589

    CrossRefPubMed
38. 38.↵
    2. Yu HJ,
    3. Christodoulou C,
    4. Bhise V, et al

    . Multiple white matter tract abnormalities underlie cognitive impairment in RRMS. Neuroimage 2012;59:3713–22 doi:10.1016/j.neuroimage.2011.10.053 pmid:22062194

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Weinstein A,
    3. Schwid SR,
    4. Schiffer RB, et al

    . Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56:319–24 pmid:10190822

    CrossRefPubMedWeb of Science
40. 40.↵
    2. La ML,
    3. Di Pietrantonj C,
    4. Rovaris M, et al

    . Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2014;7:CD009333 doi:10.1002/14651858.CD009333.pub2 pmid:25062935

    CrossRefPubMed